Original Publication Date: 1 December, 2014
Publication / Source: Lung Cancer Management
Authors: Wayne J Aston, Scott A Fisher, Andrea Khong et al.
Given the impressive efficacy of immune checkpoint blockade in thoracic malignancies, and the recently discovered immune-stimulating properties of many cytotoxic drugs, a logical next step would be to combine these treatments. However, the rational design of clinical trials investigating these combinations is hampered by a lack of knowledge regarding the overall immunogenic effects of the different chemotherapeutics.